Generic drugs provide huge savings to the healthcare industry. In the past, the commission has taken action, handing out large fines to pharmaceutical companies for delaying generic entry.
However, almost three-quarters of 125 patent settlements in the EU in 2015 between originator pharmaceutical and their generic competitors resulted in a lengthening of time to bring the cheaper generic version to market.
But of those 74%, only 10% were settlements limiting generic market entry and including a payment or transfer of value from originator to generic company, while 64% were settlements limiting generic entry but with no value transfer. The remaining 26% of settlements were those that did not limit generic market entry, according to a new European Commission report released Tuesday.